Product Description
TRU-015, being developed by Trubion Pharmaceuticals Inc and Pfizer Inc, is an intravenously administered anti-CD20 IgG fusion protein for the treatment of rheumatoid arthritis. TRU-015 depletes B-cells from the peripheral blood in vitro, and can mediate complement-and antibody-dependent cellular cytotoxicity. TRU-015 was well tolerated in patients with rheumatoid arthritis in phase I and II clinical trials, and demonstrated an efficacy profile similar to other biological agents approved for rheumatoid arthritis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20140823/)
Mechanisms of Action: CD20 Antagonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Lymphoma, B-Cell
Phase 1: Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Glomerulonephritis, Membranous|Lupus Nephritis|Lupus Erythematosus, Systemic|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2007-006150-25 | P2 |
Completed |
Arthritis, Rheumatoid |
2010-06-28 |
|
| 3206K1-2203 | P2 |
Terminated |
Arthritis, Rheumatoid |
2010-02-01 |
|
| 3206K3-103 | P1 |
Terminated |
Lupus Nephritis|Lupus Erythematosus, Systemic|Glomerulonephritis, Membranous|Kidney Diseases |
2008-05-01 |
|
| 3206K2-104 | P1 |
Terminated |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2008-04-01 |
42% |